Foundayo (Orforglipron): Cost, Side Effects, Dosing & Where to Buy in 2026

Foundayo (orforglipron) is the first non-peptide oral GLP-1 medication for weight loss, FDA-approved on April 1, 2026. It costs $149-$299/month self-pay through LillyDirect, produces 11-12% body weight loss in clinical trials, and can be taken any time of day without food or water restrictions — the only GLP-1 pill with that convenience. It is manufactured by Eli Lilly, the same company behind Zepbound and Mounjaro.

Foundayo's approval was the fastest for a new molecular entity since 2002 — just 50 days from filing to FDA approval under the National Priority Voucher program. Prescriptions are being accepted now through LillyDirect, with broader telehealth and retail pharmacy availability rolling out through April 2026.

This guide covers what Foundayo is, how it works, clinical trial data, side effects with exact percentages, the full dosing schedule, pricing across channels, and how it compares to Wegovy and Zepbound. For a head-to-head comparison with the other oral option, see our Foundayo vs Wegovy Pill comparison.

What Is Foundayo and How Is It Different?

Foundayo's active ingredient, orforglipron, is a non-peptide small molecule GLP-1 receptor agonist. Every other GLP-1 on the market — Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus — is based on modified peptides (synthetic versions of natural hormones). This matters for a practical reason:

Peptides get destroyed in the stomach. That's why most GLP-1s are injections, and why oral semaglutide (Wegovy pill, Rybelsus) requires a special absorption enhancer called SNAC — which forces you to take it on an empty stomach with no more than 4 oz of plain water, then wait 30 minutes before eating or drinking anything else.

Orforglipron is not a peptide, so it survives the stomach on its own. No absorption enhancer needed. No food restrictions. No water restrictions. Take it any time of day, with or without meals. This is Foundayo's single biggest practical advantage over every other GLP-1 option.

Clinical Trial Results: How Much Weight Does Foundayo Help You Lose?

Foundayo was studied in the ATTAIN clinical trial program. The pivotal trial for obesity was ATTAIN-1, published in the New England Journal of Medicine.

ATTAIN-1 results (3,127 adults with obesity, 72 weeks):

For context, the STEP 1 trial showed injectable semaglutide (Wegovy 2.4mg) produced 14.9% weight loss at 68 weeks, and SURMOUNT-1 showed tirzepatide (Zepbound 15mg) produced 22.5% at 72 weeks. Foundayo's 11-12% falls below both — but it is a pill with zero dosing restrictions, which is a meaningful tradeoff for many patients.

ATTAIN-2 studied Foundayo in patients with obesity AND type 2 diabetes: 10.5% mean weight loss (22.9 lbs) plus a 1.8% reduction in HbA1c at the highest dose.

ATTAIN-MAINTAIN (the first study of its kind) showed that patients who switched from injectable semaglutide or tirzepatide to oral Foundayo maintained most of their weight loss, with modest regain of approximately 5 kg compared to 9 kg on placebo. This positions Foundayo as a viable oral maintenance option after initial injectable treatment.

Foundayo Side Effects: What the Data Shows

Like all GLP-1 medications, Foundayo's most common side effects are gastrointestinal. The rates below are from the official FDA prescribing information:

Discontinuation rates due to side effects: 10% at the 17.2 mg dose vs 3.2% on placebo. Most GI side effects were mild to moderate, occurred during dose escalation, and decreased over time.

Boxed warning: Like all GLP-1 medications, Foundayo carries a boxed warning about thyroid C-cell tumors observed in rodent studies with other GLP-1 agonists. Notably, orforglipron itself did not produce tumors in rodents (it is not pharmacologically active in rodent GLP-1 receptors), but the class warning is required. Foundayo is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Five mild cases of pancreatitis were confirmed across the ATTAIN-1 trial. Patients should report severe, persistent abdominal pain to their healthcare provider immediately.

Foundayo Dosing Schedule

Foundayo uses a gradual titration schedule with six dose levels. Each step lasts at least 30 days to minimize GI side effects:

Total time to reach maximum dose: approximately 5 months. Your provider may adjust the pace based on your tolerability and response. Some patients achieve meaningful weight loss at the 9 mg or 14.5 mg dose and don't need to escalate to 17.2 mg.

Foundayo Cost and Pricing in April 2026

Foundayo pricing is structured by dose level, with self-pay prices available through LillyDirect:

Lilly savings card: Covers up to $100/month for a 1-month fill, $200 for 2-month, $300 for 3-month. Annual cap of $1,000. Expires December 31, 2026. Available to commercially insured patients. Check eligibility at foundayo.lilly.com.

For comparison, oral Wegovy (semaglutide) starts at $149/month for the lowest dose through NovoCare. The self-pay pricing is competitive at the starting dose, though Foundayo's maintenance dose ($299/month) is in line with other brand-name GLP-1 programs. See our full cost comparison across 39 providers for the complete pricing picture.

How Does Foundayo Compare to Other GLP-1 Medications?

Choose Foundayo if: Dosing convenience is your top priority. You want a pill you can take any time without food/water restrictions. You're switching from an injectable and want an oral maintenance option (ATTAIN-MAINTAIN trial supports this). You prefer a Lilly product and want to stay in their ecosystem (Zepbound → Foundayo step-down).

Choose Wegovy (oral or injection) if: Maximum weight loss matters most to you. You want fewer GI side effects with the pill form. You have cardiovascular disease (the SELECT trial showed cardiovascular benefits for semaglutide — no equivalent data exists for orforglipron yet).

Choose Zepbound if: You want the highest weight loss possible (20%+) and don't mind a weekly injection. The dual GIP + GLP-1 mechanism produces meaningfully more weight loss than any single-agonist option.

For a deeper comparison of the two oral options, see our Foundayo vs Wegovy Pill analysis. For a broader drug comparison, read Semaglutide vs Tirzepatide.

Where to Get Foundayo Online

As of April 7, 2026, Foundayo is available through the following channels:

LillyDirect (available now): Eli Lilly's direct-to-patient platform began accepting Foundayo prescriptions immediately after approval, with shipping starting April 6, 2026. Fulfillment is through Prescryptive and Amazon Pharmacy. Visit LillyDirect.

Telehealth providers: Broad telehealth availability is rolling out through April 2026. Providers that already prescribe brand-name GLP-1s — including platforms in our provider rankings like Ro, Fridays, and Found — are expected to add Foundayo as an option. We will update individual provider reviews as each platform confirms Foundayo availability.

Retail pharmacies: Lilly has announced that broad retail pharmacy availability will follow the initial LillyDirect rollout. Major chains including CVS, Walgreens, and independent pharmacies will carry Foundayo.

Foundayo Eligibility: Who Qualifies?

Foundayo is FDA-approved for adults who meet the same criteria as other weight loss GLP-1 medications:

• •BMI of 30 or higher (obesity), OR
• •BMI of 27 or higher with at least one weight-related condition: type 2 diabetes, high blood pressure, high cholesterol, cardiovascular disease, obstructive sleep apnea, NAFLD/NASH, or PCOS
• •Must be 18 or older (not yet approved for adolescents, unlike Wegovy)
• •Use in combination with a reduced-calorie diet and increased physical activity

Not sure if you qualify? Use our GLP-1 eligibility checker for a quick preliminary assessment. A healthcare provider will make the final determination based on your complete medical history.

Frequently Asked Questions About Foundayo

Is Foundayo the same as Zepbound?

No. Both are made by Eli Lilly, but they are different drugs. Zepbound contains tirzepatide (a dual GIP + GLP-1 agonist given as a weekly injection). Foundayo contains orforglipron (a GLP-1-only agonist taken as a daily pill). Zepbound produces greater weight loss (20%+ vs 11-12%), but Foundayo offers the convenience of an oral pill with no food restrictions.

Can I switch from Zepbound or Wegovy to Foundayo?

Yes. The ATTAIN-MAINTAIN trial specifically studied patients switching from injectable semaglutide or tirzepatide to Foundayo. Patients maintained most of their weight loss, with modest regain of about 5 kg over 52 weeks (vs 9 kg regain on placebo). Discuss the transition plan with your prescribing provider.

Does insurance cover Foundayo?

Coverage is still rolling out as of April 2026. Commercial insurance plans are in the process of adding Foundayo to formularies. Lilly offers a savings card that brings commercially insured patients down to as low as $25/month. Medicare Part D is expected to cover Foundayo starting with the GLP-1 Bridge program in July 2026 at approximately $50/month copay. Use our insurance coverage lookup tool to check your specific plan.

Why are Foundayo's side effects higher than Wegovy pill?

Orforglipron is a partial agonist with a different signaling profile than semaglutide at the GLP-1 receptor. It favors cAMP signaling over beta-arrestin recruitment, which may partly explain the higher GI rates. That said, most side effects are mild to moderate, occur during dose escalation, and decrease over time. The 10% discontinuation rate at the highest dose is in line with other GLP-1 medications.

How long until I see results on Foundayo?

Based on clinical trial data, meaningful weight loss begins during the dose escalation phase (months 2-3) and continues to increase through month 6-8. The full titration to the maximum 17.2 mg dose takes approximately 5 months. Most patients in ATTAIN-1 who completed the full 72-week treatment period achieved 10%+ body weight loss.

The Bottom Line on Foundayo

Foundayo fills a real gap in the GLP-1 landscape: it's the only weight loss pill you can take without thinking about food timing, water restrictions, or injection anxiety. The tradeoff is lower weight loss (~12%) compared to injectable options (~15-23%) and slightly more GI side effects than oral semaglutide.

For patients who have been on the fence about starting a GLP-1 because they don't want injections or can't deal with oral semaglutide's rigid dosing rules, Foundayo removes those barriers. For patients already on injectables who want to transition to a pill for long-term maintenance, the ATTAIN-MAINTAIN data supports that path.

At $299/month self-pay for maintenance doses (or as low as $25/month with commercial insurance + savings card), pricing is competitive with other brand-name options. The real question is whether your insurance will cover it yet — and that's a moving target as formularies update through mid-2026.

Not sure which GLP-1 is right for you? Our provider match quiz can pair you with the right program in under 2 minutes, or check the full provider rankings to compare all 39 telehealth options side-by-side.

Sources